Gary S. Stetz II bought $25k of HEPA
director at Hepion Pharmaceuticals, Inc.. 500,000 shares at an average of $0.05, traded Aug 3, 2026, filed Aug 12, 2026.
Score components
- +15RoleDirector
- +5Trade size$25k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +4Price context24% below the 52-week high
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-037500, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | POpen-market purchase Common Stock | +500,000 | $0.05 | $25k | 500,000 | Aug 12, 2026 |
| Aug 3, 2026 | POpen-market purchase Warrantsderivative | +500,000 | $0.00 | $0 | 500,000 | Aug 12, 2026 |
Related signals
Other insiders at Hepion Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HEPAbuy Hepion Pharmaceuticals, Inc. | Danina Fisher director | $10k 200,000 shares | - | |
| 59Moderate | Hepion Pharmaceuticals, Inc. | Sireesh Appajosyula Chief Operating Officer | $100k 2,000,000 shares | +160% | |
| 67Notable | Hepion Pharmaceuticals, Inc. | Vincent S LoPriore Executive Chairman | $500k 10,000,000 shares | +160% | |
| 54Moderate | Hepion Pharmaceuticals, Inc. | Michael J. Purcell director | $100k 2,000,000 shares | +160% | |
| 64Notable | Hepion Pharmaceuticals, Inc. | Gary S. Stetz Interim CEO | $100k 2,000,000 shares | +160% | |
| 53Moderate | Hepion Pharmaceuticals, Inc. | Sireesh Appajosyula Chief Operating Officer | $50k 1,250,000 shares | - | |
| 63Notable | Hepion Pharmaceuticals, Inc. | Gary S. Stetz Interim CEO | $50k 1,250,000 shares | - | |
| 64Notable | Hepion Pharmaceuticals, Inc. | Vincent S LoPriore Executive Chairman | $250k 6,250,000 shares | - | |
| 53Moderate | Hepion Pharmaceuticals, Inc. | Michael J. Purcell director | $50k 1,250,000 shares | - | |
| 33Weak | HEPAbuy Hepion Pharmaceuticals, Inc. | Peter Wijngaard director | $15k 5,000 shares | +111% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.